- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05913713
HIIT etter brystkreftkjemoterapi
Intervalltrening med høy intensitet: Optimalisering av treningsterapi for å redusere risikoen for kardiovaskulær sykdom etter brystkreftkjemoterapi
Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Gainesville, Florida, Forente stater, 32611
- Integrative Cardiovascular Physiology Laboratory, University of Florida
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- female patients based on biological sex
- 18 to 85 years of age
- diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer
- completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation
- absence of contraindications to exercise or to participate in study
- study clinician approval
Exclusion Criteria:
- do not meet inclusion criteria
- scheduled to receive surgery or radiation therapy during the intervention period
- any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
- lymphedema stage ≥2 prior to study enrollment
- are pregnant
- current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: High Intensity Interval Training (HIIT)
Supervised home-based high-intensity interval training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks. |
Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period. After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises. |
|
Eksperimentell: Moderate Intensity Continuous Training (MICT)
Supervised home-based moderate-intensity continuous training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks. |
Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period. After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises. |
|
Annen: Usual Care (UC)
Research participants will continue their habitual physical activity for the duration of the study. Once they complete the study, they will have the opportunity to perform supervised HIIT or MICT at home for 3 days/week for 12 weeks (research participants can choose either type of exercise). |
Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period. After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in brachial FMD
Tidsramme: Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
Flow-mediated dilation (FMD) is an established non-invasive measure of endothelial function. Brachial artery FMD will be determined via ultrasonography in response to reactive hyperemia following 5-min forearm ischemia. |
Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
|
Change in cardiac function (global longitudinal strain)
Tidsramme: Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
Global longitudinal strain is a marker of acute subclinical cardiotoxicity and is recommended for monitoring cancer patients at risk of cancer therapy-related cardiac dysfunction. |
Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
|
Percent completed vs. planned exercise frequency
Tidsramme: Throughout the 12 weeks of supervised home-based exercise training
|
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise sessions/week. |
Throughout the 12 weeks of supervised home-based exercise training
|
|
Percent completed vs. planned exercise duration
Tidsramme: Throughout the 12 weeks of supervised home-based exercise training
|
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise min/session. |
Throughout the 12 weeks of supervised home-based exercise training
|
|
Percent completed vs. planned exercise intensity
Tidsramme: Throughout the 12 weeks of supervised home-based exercise training
|
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise intensity/session. |
Throughout the 12 weeks of supervised home-based exercise training
|
|
Number of participants who experience adverse events as defined by most recent CTCAE throughout the exercise intervention
Tidsramme: Throughout the 12 weeks of supervised home-based exercise training
|
To evaluate safety plans are in place for determination and monitoring of adverse events according to the most recent National Cancer Institute Common Terminology Criteria for Adverse Events. Classification for seriousness, expectedness, severity and relationship to study intervention will be based on the NIH provided definitions. |
Throughout the 12 weeks of supervised home-based exercise training
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Demetra Christou, PhD, University of Florida
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB202300460 -N
- 1R21AG078995-01A1 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .